drugset
drugset / Trial / NCT03744182

A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD

NCT03744182 ↗

Phase 1 Completed 66 enrolled Hanmi Pharmaceutical Company Limited
RandomizedSequentialDouble-blindTreatment

Summary

This study is a phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HM15211 in obese subjects with NAFLD

Timeline

Start
2018-11-01
Primary completion
2020-03-18
Completion
2020-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Efocipegtrutide Protein / enzyme biologic — —

Indications

NAFLD1